Drug delivery systems for treatment of systemic hypertension

Clinical Pharmacokinetics

Volumn 42, Issue 11, 2003, Pages 931-940

  Prisant, L Michael ^a   Elliott, William J ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALAT CC; ALGINIC ACID; ANTIHYPERTENSIVE AGENT; CALAN SR; CARDIZEM XL; CARDURA CR; CLONIDINE; CODAS; COPOLYMER; DILTIAZEM; DOXAZOSIN; DYNACIRC CR; ETHYL CELLULOSE; FELODIPINE; GEOMATRIX; HYDROCHLOROTHIAZIDE PLUS PROPRANOLOL; HYDROXYPROPYLMETHYLCELLULOSE; INDERIDE LA; ISRADIPINE; MACROGOL; METOPROLOL; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; PLASTICIZER; POLYMER; PROPANOL; PROPRANOLOL; SODAS; UNCLASSIFIED DRUG; VERAPAMIL; VERELAN PM;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DEPIGMENTATION; DROWSINESS; DRUG ABSORPTION; DRUG CAPSULE; DRUG COATING; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG METABOLISM; ENCAPSULATION; ERYTHEMA; FIRST PASS EFFECT; FLUSHING; HUMAN; HYPERPIGMENTATION; HYPERTENSION; HYPOTENSION; LIVER METABOLISM; OSMOTIC PUMP; PATIENT COMPLIANCE; PHARMACODYNAMICS; PRIORITY JOURNAL; PRURITUS; REVIEW; SKIN INDURATION; SKIN MANIFESTATION; SUSTAINED RELEASE PREPARATION; TABLET; TACHYCARDIA; TOXICITY; XEROSTOMIA;

ANTIHYPERTENSIVE AGENTS; DOSAGE FORMS; DRUG DELIVERY SYSTEMS; HUMANS; HYPERTENSION;

EID: 0042856280     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200342110-00001     Document Type: Review

References (55)

1. Prisant LM, Bottini B, DiPiro JT, et al. Novel drug-delivery systems for hypertension. Am J Med 1992; 93: 45S-55S
2. Elliott WJ, Prisant LM. Drug delivery systems for antihypertensive agents. Blood Press Monit 1997; 2: 53-60
3. Elliott WJ, Prisant LM. Controlled-release formulations of calcium antagonists. In: Epstein M, editor. Calcium antagonists in clinical medicine. Philadelphia (PA): Hanley & Belfus Inc, 2002: 139-50
4. Prisant LM. Hypertension and chronotherapy: shifting the treatment paradigm. Am J Hypertens 2001; 14: 277S-9S
5. Elliott WJ. Cyclic and circadian variations in cardiovascular events. Am J Hypertens 2001; 14: 291S-5S
6. Smolensky MH, Haus E. Circadian rhythms and clinical medicine with applications to hypertension. Am J Hypertens 2001; 14: 280S-90S
7. Smith DH. Pharmacology of cardiovascular chronotherapeutic agents. Am J Hypertens 2001; 14: 296S-301S
8. Prisant LM, Devane JG, Butler J. A steady-state evaluation of the bioavailability of chronotherapeutic oral drug absorption system verapamil PM after nighttime dosing versus immediate-acting verapamil dosed every eight hours. Am J Ther 2000; 7: 345-51
9. Mutschler E, Knauf H. Current status of sustained release formulations in the treatment of hypertension: an overview. Clin Pharmacokinet 1999; 37 Suppl. 1: 1-6
10. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1881-4
11. Rudd P, Ahmed S, Zachary V, et al. Improved compliance measures: applications in an ambulatory hypertensive drug trial. Clin Pharmacol Ther 1990; 48: 676-85
12. Hilleman DE, Mohiuddin SM, Lucas Jr BD, et al. Conversion from sustained-release to immediate-release calcium entry blockers: outcome in patients with mild-to-moderate hypertension. Clin Ther 1993; 15: 1002-10
13. Burris JF, Mroczek WJ. Transdermal administration of clonidine: a new approach to antihypertensive therapy. Pharmacotherapy 1986; 6: 30-4
14. Weber MA, Drayer JI, Brewer DD, et al. Transdermal continuous antihypertensive therapy. Lancet 1984; I: 9-11
15. Transdermal clonidine for hypertension. Med Lett Drugs Ther 1985; 27: 95-6
16. Swanson DR, Barclay BL, Wong PS, et al. Nifedipine gastrointestinal therapeutic system. Am J Med 1987; 83: 3-9
17. Chrysant SG, Cohen M. Sustained blood pressure control with controlled-release isradipine (isradipine-CR). J Clin Pharmacol 1995; 35: 239-43
18. Os I, Stokke HP. Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension. Doxazosin Investigators' Study Group. J Cardiovasc Pharmacol 1999; 33: 791-7
19. Os I, Stokke HP. Doxazosin GITS compared with doxazosin standard and placebo in patients with mild hypertension. Blood Press 1999; 8: 184-91
20. Prisant LM, Carr AA, Bottini PB, et al. Nifedipine GITS (gastrointestinal therapeutic system) bezoar. Arch Intern Med 1991; 151: 1868-9
21. Prisant LM. Transdermal clonidine skin reactions. J Clin Hypertens (Greenwich) 2002; 4: 136-8
22. Dick JB, Northridge DB, Lawson AA. Skin reactions to long-term transdermal clonidine. Lancet 1987; I: 516
23. Doe N, Seth S, Hebert LA. Skin depigmentation related to transdermal clonidine therapy [letter]. Arch Intern Med 1995; 155: 2129
24. Securon SR. Sustained-release verapamil. Drug Ther Bull 1987; 25: 47-8
25. Hoon TJ, McCollam PL, Beckman KJ, et al. Impact of food on the pharmacokinetics and electrocardiographic effects of sustained release verapamil in normal subjects. Am J Cardiol 1992; 70: 1072-6
26. McAinsh J, Baber NS, Holmes BF, et al. Bioavailability of sustained release propranolol formulations. Biopharm Drug Dispos 1981; 2: 39-48
27. Nace GS, Wood AJ. Pharmacokinetics of long acting propranolol: implications for therapeutic use. Clin Pharmacokinet 1987; 13: 51-64
28. Mishriki AA, Weidler DJ. Long-acting propranolol (Inderal LA): pharmacokinetics, pharmacodynamics and therapeutic use. Pharmacotherapy 1983; 3: 334-41
29. Sica D, Frishman WH, Manowitz N. Pharmacokinetics of propranolol after single and multiple dosing with sustained release propranolol or propranolol CR InnoPran XL) a new chronotherapeutic formulation. Heart Dis 2003; 5: 176-81
30. Webster J, Petrie JC, Jeffers TA, et al. Nicardipine sustained release in hypertension. Br J Clin Pharmacol 1991; 32: 433-9
31. Felicetta JV, Serfer HM, Cutler NR, et al. A dose-response trial of once-daily diltiazem. Am Heart J 1992; 123: 1022-6
32. Eradiri O, Midha KK. Comparison of diltiazem bioavailability from 3 market extended- release products for once-daily administration: implications of chronopharmacokinetics and dynamics. Int J Clin Pharmacol Ther 1997; 35: 369-73
33. Smith DH, Neutel JM, Weber MA. Comparisons of the effects of different long-acting delivery systems on the pharmacokinetics and pharmacodynamics of diltiazem. Am J Hypertens 1999; 12: 1030-7
34. Glasser SP, Neutel JM, Albert KS, et al. Efficacy and safety of diltiazem HCl extended release (G99) dose at nighttime (10PM) compared to placebo and to morning dosing (8AM) in moderate to severe essential hypertension [abstract]. Am J Hypertens 2002; 15: 52A
35. Prisant LM. Verapamil revisited: a transition in novel drug delivery systems and outcomes. Heart Dis 2001; 3: 55-62
36. Devane JG, Kelly JG, Geoghegan B. Pharmacokinetic and in-vitro characteristics of sustained release verapamil products. Drug Dev Ind Pharm 1990; 16: 1233-48
37. Devane JG, Kelly JG. Effect of food on the bioavailability of a multiparticulate sustained-release verapamil. Adv Ther 1991; 8: 48-53
38. Carr AA, Bottini PB, Prisant LM, et al. Once-daily verapamil in the treatment of mild-to-moderate hypertension: a double-blind placebo-controlled dose-ranging study. J Clin Pharmacol 1991; 31: 144-50
39. Sandberg A, Ragnarsson G, Jonsson UE, et al. Design of a new multiple-unit controlled-release formulation of metoprolol - metoprolol CR. Eur J Clin Pharmacol 1988; 33: S3-7
40. Sandberg A, Blomqvist I, Jonsson UE, et al. Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: a comparison with conventional tablets. Eur J Clin Pharmacol 1988; 33: S9-14
41. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7
42. Blychert E, Wingstrand K, Edgar B, et al. Plasma concentration profiles and antihypertensive effect of conventional and extended-release felodipine tablets. Br J Clin Pharmacol 1990; 29: 39-45
43. Feig PU, Gibson L, MacCarthy EP, et al. The efficacy and safety of once-daily nifedipine coat-core in the treatment of mild-to-moderate hypertension. Adalat CC Cooperative Study Group. Clin Ther 1993; 15: 963-75
44. Plosker GL, Faulds D. Nisoldipine coat-core: a review of its pharmacology and therapeutic efficacy in hypertension. Drugs 1996; 52: 232-53
45. Schaefer HG, Heinig R, Ahr G, et al. Pharmacokinetic-pharmacodynamic modelling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-release dosage form. Eur J Clin Pharmacol 1997; 51: 473-80
46. Conte U, Maggi L. Modulation of the dissolution profiles from Geomatrix multi-layer matrix tablets containing drugs of different solubility. Biomaterials 1996; 17: 889-96
47. Graney WF. Clinical experience with a once-daily, extended-release formulation of diltiazem in the treatment of hypertension. Am J Med 1992; 93: 56S-64S
48. Prisant LM. Ambulatory blood pressure profiles in patients treated with once-daily diltiazem extended-release or indapamide alone or in combination. Am J Ther 2000; 7: 177-84
49. Whelton A, Eff J, Magner DJ. Sustained antihypertensive activity of diltiazem SR: double-blind, placebo-controlled study with 24-hour ambulatory blood pressure monitoring. J Clin Pharmacol 1992; 32: 808-15
50. Chung M, Reitberg DP, Gaffney M, et al. Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system: a controlled-release formulation of nifedipine. Am J Med 1987; 83: 10-4
51. Kreiling KM, Hampers LC, Baum CR. Special feature: picture of the month. Ingestion of nifedipine sustained-release tablets. Arch Pediatr Adolesc Med 2000; 154: 1161-2
52. Chung M, Vashi V, Puente J, et al. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol 1999; 48: 678-87
53. Weber MA, Drayer JI, McMahon FG, et al. Transdermal administration of clonidine for treatment of high BP. Arch Intern Med 1984; 144: 1211-3
54. Maibach H. Clonidine: irritant and allergic contact dermatitis assays. Contact Dermatitis 1985; 12: 192-5
55. Maibach HI. Oral substitution in patients sensitized by transdermal clonidine treatment. Contact Dermatitis 1987; 16: 1-8